Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Family presence during resuscitation of a child remains controversial and disagreement persists about whether and when potential benefits outweigh risks.
AMA J Ethics. 2018;20(5):507-512. doi:
10.1001/journalofethics.2018.20.5.sect1-1805.